ZBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Zenas Biopharma Inc (ZBIO) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. Despite the recent price decline, the stock has strong long-term growth potential driven by its pipeline assets, and analysts remain optimistic about the approval and commercial success of obexelimab. The technical indicators and options data suggest a neutral to slightly bullish sentiment, making this a favorable entry point for long-term investors.
The technical indicators show a bullish trend with SMA_5 > SMA_20 > SMA_200. The MACD histogram is positive at 0.53, indicating bullish momentum, though it is contracting. RSI is at 67.145, which is neutral and not overbought. Key support is at 23.804, and resistance is at 28.8, suggesting the stock has room to move higher in the short term.
Analysts are optimistic about the approval and commercial success of obexelimab, with Wedbush adding ZBIO to its Best Ideas List.
The stock is trading at a discount, with Citi highlighting it as a buying opportunity for long-term investors.
Technical indicators show a bullish trend, and options data suggests slightly bullish sentiment.
Morgan Stanley downgraded the stock due to weaker-than-expected Phase 3 results for obexelimab, which may limit its peak market share.
The stock has experienced a recent price decline of -1.67%, and broader market conditions (S&P 500 down -1.01%) may weigh on short-term performance.
In Q3 2025, Zenas Biopharma reported a net income loss of -$51.5M, which is an improvement of 33.4% YoY. EPS also improved by 32.61% YoY to -1.22. The company has no revenue yet, but its gross margin remains at 100%. These financials indicate the company is still in its growth and development phase, with improving cost management.
Analysts are mixed but lean positive. Wedbush has an Outperform rating and sees strong long-term growth potential. Citi maintains a Buy rating with a price target of $43, down from $46, citing confidence in obexelimab's approval. Morgan Stanley downgraded the stock to Equal Weight with a price target of $19, citing weaker-than-expected Phase 3 results but still acknowledges a place for obexelimab in the market.
